Average weekly weight loss on Wegovy: what the trial data actually shows

Step 1: the dose-escalation phase, where most early loss happens

Wegovy does not start at full strength. The licensed schedule runs from 0.25 mg up through 0.5 mg, 1.0 mg and 1.7 mg before reaching the 2.4 mg maintenance dose, with roughly four weeks at each level. During this titration phase, appetite suppression is already building, and for many people this is when weekly losses feel most noticeable, with our page on weekly weight loss on Wegovy showing how figures like 0.3–0.5 kg in a single week compare across the dose stages.

That early pace rarely holds. The body adapts, energy expenditure adjusts, and the rate of loss tends to taper. This is not a sign that Wegovy has stopped working; it is normal physiology. The STEP 1 trial data shows the steepest curve in weeks 1–20, with the slope flattening through the back half of the 68-week study. If you want a closer look at how the picture develops specifically in the first weeks, our page on how long Wegovy takes to work covers that phase in detail.

Side effects, particularly nausea and loose stools, are most common at the start and after each dose increase. They often ease within a week or two. Severe or persistent stomach pain that radiates to the back warrants prompt medical attention, as the MHRA has flagged acute pancreatitis as an infrequent but serious risk with GLP-1 medicines. Report any suspected side effects through the MHRA Yellow Card scheme.

Step 2: maintenance dose and the 68-week average

Once someone reaches and holds the 2.4 mg weekly dose, the trial average settles at around 15% of starting body weight over the full 68-week STEP 1 period. For a person beginning treatment at 100 kg, that is approximately 15 kg total, which averages out at just under 0.22 kg per week across the whole study, though any single week may look very different from that number.

It is worth understanding what drives variation in that average. Participants who reached the full 2.4 mg dose and sustained it through 68 weeks tended to show the larger losses. Those who stopped early, required dose reductions because of side effects, or had lower starting weights naturally contributed smaller totals to the mean. The full breakdown of average weight loss on Wegovy explores how starting BMI and other factors shift the numbers.

For context on how this stacks up at the one-year mark specifically, the Wegovy one-year results page pulls together the longer-term trial data alongside real-world considerations.

Step 3: the 7.2 mg dose and what it means for weekly averages

The MHRA approved a higher maintenance dose of 7.2 mg on 14 April 2026, first available as three 2.4 mg pens per week and then as a dedicated single-dose pen. Trial data for the 7.2 mg dose reported around 20.7% average weight loss over 72 weeks, a meaningful step up from the 15% seen at 2.4 mg, and closer to the results achieved with tirzepatide (Mounjaro) at its highest dose. The MHRA's announcement on the 7.2 mg pen confirms it is licensed for adults with a BMI of 30 or above.

On a weekly basis, that 20.7% over 72 weeks works out at roughly 0.25–0.30 kg per week on average, again front-loaded in the earlier months. The pen itself (a single pre-set auto-dosing device with a covered needle that locks after use) arrives tracked and in plain packaging, the same DPD next-working-day delivery used across all our dispensing. Availability of specific dose formats is confirmed at the time of your consultation rather than assumed.

For a broader picture of what the weekly number means in practice across the full Wegovy range, the per-week average data page sets out the figures by dose and time point.

What actually moves the weekly number

The trial average is a population mean. Your own weekly loss will reflect your starting weight (heavier starting points often produce larger absolute losses in the early weeks), how consistently you tolerate and maintain your dose, what you eat alongside treatment, and how much lean-muscle activity you build in. Wegovy reduces appetite substantially; it does not override diet entirely.

Sleep, stress and underlying metabolic conditions all play a role too. Prescribers at regulated UK services review progress at each repeat, not to gatekeep, but because the clinical picture genuinely changes over months and the dose or plan may need adjusting. That review sits at the centre of responsible prescribing, and it is why the overall weight-loss data for Wegovy should be read as a reference range rather than a personal forecast.

If you are weighing up Wegovy against other licensed treatments, our weight-loss treatment overview sets out the options clearly. When you are ready to speak with a prescriber, a free consultation is the starting point, reviewed the same day by a real clinician, not automated software.